Background The World Health Organization (WHO) End TB Strategy stresses universal
access to drug susceptibility testing (DST). DST determines whether Mycobacterium …

Background Tuberculosis is a leading cause of infectious disease‐related death and is one
of the top 10 causes of death worldwide. The World Health Organization (WHO) …

Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

Background Accurate and rapid detection of tuberculosis (TB) and drug resistance are
critical for improving patient care and decreasing the spread of TB. Xpert® MTB/RIF assay …

Background Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the
newest version, are the only World Health Organization (WHO)‐recommended rapid tests …

Background Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health
Organization (WHO)‐recommended rapid tests that simultaneously detect tuberculosis and …

Background Xpert MTB/RIF Ultra (Xpert Ultra) and Xpert MTB/RIF are World Health
Organization (WHO)‐recommended rapid nucleic acid amplification tests (NAATs) widely …

Summary Background The WHO End TB Strategy requires drug susceptibility testing and
treatment of all people with tuberculosis, but second-line diagnostic testing with line-probe …

Background The World Health Organization (WHO) recommends Xpert MTB/RIF in place of
smear microscopy to diagnose tuberculosis (TB), and many countries have adopted it into …

Background Every year, at least one million children become ill with tuberculosis and
around 200,000 children die. Xpert MTB/RIF and Xpert Ultra are World Health Organization …